{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=65", "query": { "condition": "Randomized Controlled Study", "page": 65 }, "page_size": 10 }, "pagination": { "page": 65, "page_size": 10, "total_count": 15138, "total_pages": 1514, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=66&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=64&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T23:22:29.081Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03770689", "title": "Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Rectal Cancer" ], "interventions": [ { "name": "Peposertib 50 mg", "type": "DRUG" }, { "name": "Peposertib 100 mg", "type": "DRUG" }, { "name": "Peposertib 150 mg", "type": "DRUG" }, { "name": "Peposertib 250 mg", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-03-20", "completion_date": "2022-02-21", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 10, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Great Neck", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770689" }, { "nct_id": "NCT01008410", "title": "Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Proctitis", "Proctosigmoiditis" ], "interventions": [ { "name": "Budesonide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2009-11-17", "completion_date": "2013-04-29", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "National City", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008410" }, { "nct_id": "NCT06425159", "title": "A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Generalized Epilepsy" ], "interventions": [ { "name": "BHV-7000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 27, "start_date": "2024-06-20", "completion_date": "2026-03-12", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06425159" }, { "nct_id": "NCT01742208", "title": "Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Sotagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2013-02", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2020-02-12", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 7, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742208" }, { "nct_id": "NCT00111189", "title": "A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Paliperidone Palmitate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 414, "start_date": "2005-02", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 18, "location_summary": "Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111189" }, { "nct_id": "NCT01545050", "title": "Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Placebo matching with BMS-945429", "type": "BIOLOGICAL" }, { "name": "BMS-945429", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2012-06", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 8, "location_summary": "La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545050" }, { "nct_id": "NCT03823391", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "ABBV-3373", "type": "DRUG" }, { "name": "Placebo for ABBV-3373", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo for adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 48, "start_date": "2019-03-27", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2021-07-19", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03823391" }, { "nct_id": "NCT01892189", "title": "Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ketamine-Induced Brain Activity Changes", "Psychotic-like Symptoms" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "TAK-063", "type": "DRUG" }, { "name": "TAK-063 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 27, "start_date": "2013-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892189" }, { "nct_id": "NCT01633060", "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 432, "start_date": "2012-10-03", "completion_date": "2017-09-21", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 37, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01633060" }, { "nct_id": "NCT02347176", "title": "Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Tralokinumab Dose 1", "type": "BIOLOGICAL" }, { "name": "Tralokinumab Dose 2", "type": "BIOLOGICAL" }, { "name": "Tralokinumab Dose 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 204, "start_date": "2015-01-23", "completion_date": "2016-02-05", "has_results": true, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-10-28T23:22:29.081Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fremont", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02347176" } ] }